← Leaderboards
Makedonka Mitreva
Washington University
$12,990,587
Attributed
$21,037,704
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,037,704 · 11
By mechanism
R01$19,260,973 · 8
R56$696,640 · 1
U01$627,224 · 1
R21$452,867 · 1
Top collaborators
- James W Janetka12 shared
- Sara Lustigman7 shared
- Warwick Grant5 shared
- Miguel Mauricio Cabada4 shared
- Judy Sakanari4 shared
- Arlene Dent2 shared
- Peter Uwe Fischer1 shared
Most similar at Washington University
Same institution · by research overlap
- James W Janetka$9,104,937
- Warwick Grant$1,648,996
Others in their field
Top investigators on “Parasites”
- Stephen Lev Hoffman · Sanaria, Inc.$58,168,134
- L David Sibley · Washington University$47,818,729
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,087,946
- Wilhelmus G. J. Hol · University Of Washington$32,390,237
- Philip Jon Rosenthal · University Of California San Francisco$31,794,731
- Daniel F. Hoft · Saint Louis University$31,137,771
Research focus
ParasitesPharmaceutical PreparationsNematodaInfectionLeadAreaMorbidity - Disease RateAdultNovel TherapeuticsGenomicsGenesMolecularAffectPathway InteractionsInnovationProteinsPathogenCommunitiesStructureGenomeBiologicalBaseParasitic NematodeBasic Science
Grant awards (43)
Innovative therapeutic strategies to support elimination of river blindness$805,959
R01 · FY2025 · AI · contact PI
Advancing lymphatic filariasis elimination with parasite genomic epidemiology$777,360
R01 · FY2025 · AI · contact PI
Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs$721,872
R01 · FY2025 · AI · contact PI
Population genomics and new tools for the endgame of onchocerciasis elimination in Africa$614,567
R01 · FY2025 · AI · contact PI
Innovative therapeutic strategies to support elimination of river blindness$805,271
R01 · FY2024 · AI · contact PI
Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs$759,307
R01 · FY2024 · AI · contact PI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$410,000
R01 · FY2024 · EY · contact PI
Innovative therapeutic strategies to support elimination of river blindness$834,159
R01 · FY2023 · AI · contact PI
Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs$773,850
R01 · FY2023 · AI · contact PI
Population genomics and new tools for the endgame of onchocerciasis elimination in Africa$646,373
R01 · FY2023 · AI · contact PI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$410,000
R01 · FY2023 · EY · contact PI
Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs$788,290
R01 · FY2022 · AI · contact PI
Population genomics and new tools for the endgame of onchocerciasis elimination in Africa$654,676
R01 · FY2022 · AI · contact PI
Markers of Triclabendazole Resistant Fascioliasis in the Highlands of Peru$483,573
R01 · FY2022 · AI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$397,700
R01 · FY2022 · EY · contact PI
Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs$817,605
R01 · FY2021 · AI · contact PI
Population genomics and new tools for the endgame of onchocerciasis elimination in Africa$672,891
R01 · FY2021 · AI · contact PI
Markers of Triclabendazole Resistant Fascioliasis in the Highlands of Peru$487,857
R01 · FY2021 · AI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$409,999
R01 · FY2021 · EY · contact PI
Population genomics and new tools for the endgame of onchocerciasis elimination in Africa$709,484
R01 · FY2020 · AI · contact PI
Markers of Triclabendazole Resistant Fascioliasis in the Highlands of Peru$497,882
R01 · FY2020 · AI
Innate Immune Training by Human Malaria$199,943
R21 · FY2020 · AI
COMPARATIVE GENOMICS OF PARASITIC NEMATODES$696,640
R56 · FY2019 · AI · contact PI
Markers of Triclabendazole Resistant Fascioliasis in the Highlands of Peru$533,713
R01 · FY2019 · AI
EVOLUTION OF THE NEMATODE INTESTINE, A KEY HOST INTERFACE$291,450
R01 · FY2019 · GM · contact PI
Innate Immune Training by Human Malaria$252,924
R21 · FY2019 · AI
COMPARATIVE GENOMICS OF PARASITIC NEMATODES$420,772
R01 · FY2018 · AI · contact PI
EVOLUTION OF THE NEMATODE INTESTINE, A KEY HOST INTERFACE$281,744
R01 · FY2018 · GM · contact PI
COMPARATIVE GENOMICS OF PARASITIC NEMATODES$380,708
R01 · FY2017 · AI · contact PI
EVOLUTION OF THE NEMATODE INTESTINE, A KEY HOST INTERFACE$275,491
R01 · FY2017 · GM · contact PI
COMPARATIVE GENOMICS OF PARASITIC NEMATODES$381,047
R01 · FY2016 · AI · contact PI
EVOLUTION OF THE NEMATODE INTESTINE, A KEY HOST INTERFACE$287,107
R01 · FY2016 · GM · contact PI
COMPARATIVE GENOMICS OF PARASITIC NEMATODES$405,180
R01 · FY2015 · AI · contact PI
EVOLUTION OF THE NEMATODE INTESTINE, A KEY HOST INTERFACE$250,242
R01 · FY2014 · GM · contact PI
COMPARATIVE GENOMICS OF PARASITIC NEMATODES$289,748
R01 · FY2013 · AI · contact PI
EVOLUTION OF THE NEMATODE INTESTINE, A KEY HOST INTERFACE$238,739
R01 · FY2013 · GM · contact PI
COMPARATIVE GENOMICS OF PARASITIC NEMATODES$308,241
R01 · FY2012 · AI · contact PI
EVOLUTION OF THE NEMATODE INTESTINE, A KEY HOST INTERFACE$249,833
R01 · FY2012 · GM · contact PI
COMPARATIVE GENOMICS OF PARASITIC NEMATODES$308,241
R01 · FY2011 · AI · contact PI
EVOLUTION OF THE NEMATODE INTESTINE, A KEY HOST INTERFACE$254,187
R01 · FY2011 · GM · contact PI
COMPARATIVE GENOMICS OF PARASITIC NEMATODES$311,355
R01 · FY2010 · AI · contact PI
COMPARATIVE GENOMICS OF PARASITIC NEMATODES$314,500
R01 · FY2009 · AI · contact PI
A Genomic Approach to Parasites From the Phylum Nematoda$627,224
U01 · FY2007 · AI · contact PI